Vitiligo and alopecia areata are common, disfiguring skin diseases. Treatment options are limited and include nontargeted approaches, such as corticosteroids, topical calcineurin inhibitors, narrow band ultraviolet B phototherapy, and other immune-modifying agents. The purpose of this article is to review shared, novel mechanisms between vitiligo and alopecia areata, as well as discuss how they inform the development of future targeted treatments.
INTRODUCTION
Vitiligo and alopecia areata are common, disfiguring autoimmune diseases of the skin, however their outward appearances greatly differ; vitiligo manifests as white patches on the skin whereas alopecia areata exhibits patchy hair loss. Until recently, these clinical differences made mechanistic similarities seem unlikely.
Autoimmune diseases have been traditionally categorized by medical subspecialty and target tissue. Although this is useful for clinical purposes, it often leads to oversimplification of disease pathology and implementation of general, nontargeted treatments. Over the last three decades, researchers have made significant progress understanding the immune system, which has allowed us to transition from categorizing by target tissue to immune pathogenesis. This paradigm shift has allowed for the development of targeted treatments. This is nowhere more evident than with the use of tumor necrosis factor alpha (TNFa) blockers in psoriasis, rheumatoid arthritis, and inflammatory bowel disease -three conditions affecting different target tissues brought together by a shared dependence on a single cytokine.
In this article, we will explore recently recognized similarities between vitiligo and alopecia areata, specifically regarding their dependence on inflammatory pathways for pathogenesis. We will focus on the interferon (IFN)g-driven immune response, including IFNg and IFNg-induced chemokines, and the important role of cytotoxic CD8 þ T cells. A better understanding of these mechanisms CLINICAL FEATURES AND CURRENT MANAGEMENT OF VITILIGO AND ALOPECIA AREATA Before discussing the mechanistic intricacies of autoimmunity, an understanding of clinical features and the limited management options for vitiligo and alopecia areata allows an appreciation of recent discoveries.
Vitiligo is an acquired, chronic depigmenting disorder of the skin caused by destruction of epidermal melanocytes. Estimated prevalence varies, but is often cited as 0.5-1%. Vitiligo is a condition not unfamiliar to pediatricians; of those affected by vitiligo, about a third present before age 12 years, and half before the age of 20 [1 & ]. Vitiligo can be divided into two major forms: the common form of vitiligo and its segmental variant ( Fig. 1a-c) . The common form of vitiligo is characterized by bilateral and symmetric patches of depigmentation and can progress unpredictably. In contrast, segmental vitiligo has a unilateral distribution, progresses rapidly over 6-12 months, and then stabilizes for the life of the patient.
Mainstay vitiligo treatments include topical corticosteroids, topical calcineurin inhibitors, and narrow band ultraviolet B (UVB) phototherapy. These are nontargeted approaches to treatment, and are used off-label. In fact, the only Food and
KEY POINTS
Vitiligo and alopecia areata are common disfiguring autoimmune skin diseases with limited treatment options.
The identification of IFNg as the primary contributing signaling pathway has enabled us to strategize new treatment approaches for vitiligo and alopecia areata.
Proof of concept case studies and small clinical trials have shown promise for inhibitors of IFNg, including JAK inhibitors. Drug Administration approved treatment is monobenzone cream (Benoquin), which permanently depigments, rather than repigments, the skin. In rapidly progressing cases, systemic treatments such as corticosteroids can also be considered. According to a recent Cochrane systematic review, the evidence for treatment efficacy is limited because of significant variations in study design and outcome measures [2] . Anecdotally, the efficacy is moderate, and more sophisticated vitiligo treatments are long overdue. In contrast, alopecia areata is an acquired form of nonscarring hair loss. For many patients, disease onset is before the age of 30 and it is thus also a familiar condition to pediatricians [3] . Disease severity ranges from small patches of alopecia ( Fig. 1d ), to complete loss of scalp hair (alopecia totalis), or remaining body hair, or both (alopecia universalis). Approximately 50 percentage of patients experience spontaneous hair regrowth within 1 year, although most will relapse [4, 5] . The unpredictable course of the disease causes significant psychological distress.
Much like vitiligo, available therapies are nontargeted, which likely explains their underwhelming results. Potential treatments include topical corticosteroids, intralesional corticosteroids, contact dermatitis with chemicals such as diphenylcyclopropenone or squaric acid, or systemic immunosupressants such as corticosteroids or methotrexate. Response to treatment varies widely and there are few well designed clinical trials to properly evaluate efficacy [5] .
Despite these clinical differences, vitiligo and alopecia areata share clinical commonalities. Both have a patchy distribution and are minimally symptomatic, unlike more inflammatory skin diseases like psoriasis or atopic dermatitis. Both are associated with other autoimmune conditions, specifically thyroid autoimmunity, with an estimated prevalence as high as 19 .4% with vitiligo and 28% with alopecia areata [1 & ,4]. Both conditions also appear to occur more commonly together than expected by chance, with a reported 3-8% prevalence of vitiligo in alopecia areata patients [4] . Exploring these similarities have allowed for a better understanding of their pathogenesis.
IMMUNE SYSTEM BASICS
In an attempt to make this topic more accessible to readers, we provide a basic primer on the human immune system below. To begin, the immune system is typically divided into innate and adaptive arms. The innate immune system can be thought of as the ''front line'', composed of antigen nonspecific responses driven by neutrophils, eosinophils, natural killer cells, mast cells, antimicrobial peptides, complement, and cytokines. These innate immune responses can activate antigen-presenting cells, which carry and present antigens to T cells, the effectors of the antigenspecific adaptive immune system. Antigen-presenting cells, thus, link the innate and the adaptive immune system. Examples of antigen-presenting cells in the skin include a variety of dendritic cells within the dermis and Langerhans cells within the epidermis. The adaptive immune system is composed of T cells and B cells. T cells can be further divided into CD4 þ and CD8 þ T cells. CD4 þ T cells are regarded as T helper cells and CD8 þ T cells are cytotoxic cells. CD4 þ T helper cells recognize foreign antigen peptides bound to major histocompatibility complex (MHC) class II and support the activity of other cells of the immune response, including B cells and CD8 þ T cells, predominantly through cytokines. CD8 þ cytotoxic cells recognize foreign antigen peptides bound to MHC class I molecules and can directly destroy their targets.
Crucial to our discussion will be the Th1-mediated immune response: CD4 þ cells may stimulate CD8 þ cell division and cytotoxicity, thereby providing 'help' for CD8 þ cells [6] . The predominant Th1 cytokine is IFNg. Remembering the importance of CD8 þ T cells and IFNg will help facilitate a mechanistic understanding of vitiligo and alopecia areata autoimmunity.
AUTOIMMUNITY IN VITILIGO
Various factors have been proposed to contribute to the pathophysiology of vitiligo, including those that are genetic, environmental, and autoimmune. As with most mechanisms, there is interaction among these factors, which culminate in autoimmunity as a central player in disease pathogenesis, specifically an IFNg-driven immune response [1 & ]. To begin, a shared underlying genetic susceptibility among a number of autoimmune diseases is becoming clear. We observe this clinically, as vitiligo patients and their family members have a higher risk of other autoimmune diseases, including thyroiditis, type 1 diabetes, pernicious anemia, and Addison's disease [7] . Genome-wide association studies have identified numerous susceptibility loci encoding for immune system components. These loci involve both the innate immune system [NLRP1, IFIH1(MDA5), CASP7, C1QTNF6, TIR-domain-containing adapter-inducing interferon-b (TRIF)] and adaptive immune system (FOXP3, BACH2, CD80, CCR6, PTPN22, interleukin 2 receptor subunit alpha, granzyme B, human leukocyte antigen class I and II) [1 & , 8, 9] . The initial triggering events that lead to the activation of the immune system in vitiligo are not fully understood; however, multiple studies suggest a combination of melanocyte intrinsic defects and exposure to specific environmental factors. This is especially well described in the context of depigmentation in a subset of patients who develop vitiligo after exposure to certain chemicals. These include phenolic and catecholic chemicals found in hair dyes, other dyes, resins/adhesives, leather, and other substances [10 & ,11] . Recent in-vitro studies reveal that chemicals with similar structures as the amino acid tyrosine act as tyrosine analogs within the melanocyte, and precipitate higher cellular stress levels, increase production of reactive oxygen species, and trigger an abnormal unfolded protein response within the cells [12] [13] [14] . These events lead to activation, production, and release of proteins and cytokines involved in innate immunity (HSP70, IL-1b, IL-6, and IL-8). Importantly, IL-1b production is shown to be increased in study volunteers homozygous for the NLRP1 risk allele, and serum and skin IL-6 levels are reported to be elevated even in vitiligo patients with no clear chemical exposure. This suggests that the same mechanisms may contribute to disease pathogenesis in nonchemically induced vitiligo [10 & ]. These innate immune responses activate dendritic cells, which carry and present melanocyte-specific antigens to T cells [10 & ,15 ]. In addition, cytokines secreted by innate immune cells likely act as the initial signal to help T cells locate stressed melanocytes [10 & ,16,17] . This represents the beginning of the autoimmune response in vitiligo, ultimately leading to targeted cell killing by CD8 þ cytotoxic T cells (Fig. 2) .
As melanocytes reside far from the blood vessels in the epidermis, additional chemokine signaling mechanisms exist to promote circulating CD8 þ T-cell recruitment to peripheral tissue. Chemokines are small, secreted proteins that act as chemoattractants to guide T-cell migration. Recently, using gene expression profiling on lesional skin from patients and a mouse model of vitiligo, we discovered that IFNg and IFNg-induced chemokines (CXCL9 and CXCL10) were highly expressed in the skin and blood. Mechanistic experiments in our mouse model further indicated that IFNg and CXCL10 were functionally required for both disease progression and maintenance [18 & ,19] . More recently, a separate study demonstrated that serum CXCL10 was not only higher in patients with vitiligo compared with healthy controls, but its level was associated with disease activity and significantly decreased after successful treatment, suggesting that it may be used as a biomarker to monitor the disease activity and treatment response [20 & ]. Despite advances in understanding vitiligo pathogenesis, there are few studies on the differential role of immune system in variants of the disease. For example, segmental vitiligo is a subtype of vitiligo that presents with rapid development of unilateral lesions and subsequent clinical stability. Recent studies have suggested that segmental vitiligo may be secondary to a postzygotic, somatic mutation that leads to the development of a vulnerable subpopulation of melanocytes [21] . It appears that this local vulnerability, combined with autoimmunity, results in depigmentation limited to one area of the body. Its resistance to treatment may in part be because of the melanocyte abnormalities, and it is unclear if the targeting the IFNg-driven immune response will be more effective than current treatments.
AUTOIMMUNITY IN ALOPECIA AREATA
To better understand autoimmunity in alopecia areata, we should appreciate that hair follicles enjoy relative immune privilege. This may be accomplished through multiple mechanisms, including downregulation of MHC class I and II molecules, decreased frequency of Langerhans cells, and expression of immunosuppressive cytokines [alpha-melanocyte-stimulating hormone (a-MSH), transforming growth factor beta, IGF-1]; however, the key changes that mediate this privilege are not entirely clear.
Immune privilege seems to be critical for continued hair cycling without triggering the skin immune system to damage the follicles, and its collapse is thought to be central to the pathogenesis of alopecia areata [3, [22] [23] [24] . The initiating events that lead to this breakdown are not fully understood, but physical/emotional stress, infections, and hormones have been suggested to play a role in genetically predisposed patients [3] . Similar to vitiligo, genome-wide association studies have implicated both innate and adaptive immunity in the pathogenesis of alopecia areata [25 && ,26] . Mechanistic experiments in mouse models also indicate a predominantly Th1-mediated immune response, specifically CD8 þ NKG2Dþ T cells, as the main effectors both necessary and sufficient to induce hair loss [27 && ]. Gene expression profiling of lesional skin reveals high expression of IFNg and IFNg-induced chemokines (CXCL9, CXCL10) [28] . IFNg has been shown to expose hair follicle autoantigen to autoreactive T cells through ectopic expression of MHC class I molecule and also induces the expression of chemokines, which thus amplifies the adaptive immune response by recruiting more T cells. Subsequently, cytotoxic CD8 þ T cells accumulate in and around the hair bulb and possibly target specific autoantigens, which may include the melanogenesis-associated peptides expressed by anagen hair follicles (Fig. 2) [3, [22] [23] [24] . Consistent with this model, a recent study of global transcriptional profiling of mouse and human alopecia areata lesional skin revealed gene expression signatures indicative of cytotoxic T-cell infiltration, IFNg response, and upregulation of several g-chain cytokines involved in activation of CD8 þ NKG2Dþ T cells [27 && ]. Treating mice with IFNg, IL-2, or IL-15 Rb blocking antibodies prevented alopecia areata by reducing the accumulation of CD8 þ NKG2Dþ T cells in skin, confirming the pathogenic role of these cells in the disease pathogenesis. Interestingly, systemic inhibition of Janus kinase (JAK) proteins, downstream participants in IFNg signaling, prevented alopecia areata development in mice, and topical application of these inhibitors reversed the disease in mice with established hair loss [27 && ]. More recently, a clinical study associated alopecia areata with a Th2-mediated immune response and IL-23, and suggested targeting Th2 cytokines and IL-23 as an alternative treatment strategy [29] ; however, functional data confirming the pathogenic contribution of these cytokines are not yet available.
MECHANISTIC SIMILARITIES AND DIFFERENCES
Vitiligo and alopecia areata share many similarities in pathogenesis [30] . Increased reactive oxygen species and high cellular stress level have been suggested as the initiating trigger of the innate immune system in both diseases [10 & ,13,16,17,31-34] , genome-wide association studies have demonstrated both innate and adaptive immunity [8,9,25 && ,26] , and mechanistic studies in mouse models have specifically implicated an IFNg-driven immune response, including IFNg, IFNg-induced chemokines, and cytotoxic CD8 þ T cells as the main pathogenic factors [18 & ,19,27 && ]. There exist, however, notable differences between the two conditions. In vitiligo, epidermal melanocytes have been recognized as the autoimmune cellular targets, and melanocyte-specific peptides (gp-100, melanoma antigen recognized by T cells 1, tyrosinase) have been identified as T-cell autoantigens. Therefore, it is not surprising that immune infiltration occurs superficially within the skin's dermal-epidermal junction where melanocytes reside [30] .
In contrast, it is not clear whether the immune response in alopecia areata is against a specific cell type, and the disease autoantigens are currently unknown. Although melanogenesis-associated peptides have been suggested as top candidates, this is mainly based on the observation that alopecia areata often targets pigmented hairs and disease recovery is frequently associated with white, unpigmented hair regrowth [24] . The majority of immune infiltration in alopecia areata also occurs deeper within the skin, in and around the hair follicle bulb, which differs from the more superficial inflammation in vitiligo.
FUTURE MANAGEMENT STRATEGIES: PROOFS OF CONCEPT
The recent discoveries that an IFNg-driven immune response is critical for disease pathogenesis in both diseases suggests that targeting IFNg or its downstream effectors [IFNg receptor, JAKs, signal transducer and activator of transcription 1 (STAT1), CXCR3, or CXCL10] may be an effective strategy to develop new treatments. Importantly, different antibodies and small-molecule inhibitors have already been developed to block many of these molecules and tested in early phase clinical trials for treatment of other autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn's disease [35 & ]. Unlike vitiligo and alopecia areata, these diseases are primarily driven by cytokines other than IFNg and therefore, the results of these trials have been largely disappointing.
There has been notable recent momentum behind chemical inhibitors of the JAKs, a family of tyrosine kinase proteins essential for cytokine signaling, including IFNg. Oral tofacitinib and ruxolitinib, two JAK inhibitors with different selectivity, have been recently reported to be effective in reversing the disease in several separate cases of vitiligo and alopecia areata [ As systemic administration of JAK inhibitors may have unwanted effects because of generalized immunosuppression, a recent study tested topical ruxolitinib in a patient with alopecia universalis that was treatment resistant and reported significant hair regrowth in the applied areas [41] .
STAT1 is another protein required for IFNg signal transduction. A previous in-vitro study showed that statins, which are 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors, could block STAT1 function [42] , and a vitiligo patient was reported to improve after taking oral simvastatin [43] . To investigate whether statins have the potential to be used as a treatment for vitiligo, we tested systemic simvastatin in our mouse model, and found it to be effective in both preventing and reversing the disease [44] . We are currently analyzing the results of a small clinical trial to determine the efficacy of high-dose oral simvastatin in patients with generalized vitiligo [45] . A separate study is recruiting patients to evaluate the benefits of combining atorvastatin and UVB for the treatment of active vitiligo [46] . Interestingly, a recent study tested the efficacy of simvastatin/ezetimibe in a series of patients with alopecia areata and concluded it was effective in both reversing the hair loss and inducing a stable remission [47] .
More recently, a small study tested ustekinumab, an IL-12/IL-23p40 neutralizing antibody approved by the Food and Drug Administration for the treatment of psoriasis, in three patients with alopecia areata and reported hair regrowth in all patients. The authors concluded that treatment efficacy was because of blocking of IL-23 signaling [48] , however ustekinumab also inhibits IL-12, which may stimulate IFNg production. It is therefore possible that the treatment response was primarily because of interfering with the IFNg signaling. As with most medical treatments, these targeted therapies are seemingly not curative and recurrence is likely after cessation.
CONCLUSION
Substantial progress in understanding the key immune signaling pathways involved in the pathogenesis of vitiligo and alopecia areata, specifically an IFNg-driven immune response that includes IFNg, IFNg-induced chemokines, and cytotoxic CD8 þ T cells, has enabled researchers to pursue new treatment approaches for these disfiguring autoimmune dermatologic conditions. Recent reports of successful application of novel targeted immunotherapies in patients are promising, and support initiation of larger controlled clinical trials.
